BACKGROUND AND PURPOSE: Upper motor neuron degeneration varies in different phenotypes of MND. We used single-voxel MR spectroscopy of the primary motor cortex to detect corticomotoneuron degeneration and glial hyperactivity in different phenotypes of MND with a relatively short disease duration, contributing to further delineation of the phenotypes. MATERIALS AND METHODS: We prospectively included patients with ALS-B, ALS-L, and PMA and compared their data with those of patients with PLS and healthy controls. Each cohort consisted of 12 individuals. Disease duration was <1 year in ALS and PMA, but longer in PLS by definition. Follow-up examination was at 6 months. We measured ALSFRS-R, finger- and foot-tapping speed, and levels of the following: 1) NAAx, 2) mIns, and 3) Glx in the primary motor cortex. RESULTS: At baseline, we found significantly decreased NAAx levels and increased mIns levels in PLS. Levels of NAAx and mIns in patients with ALS-L and ALS-B were not significantly different from those in controls, but NAAx levels were significantly lower compared with those in PMA. At follow-up, only in PMA was a decrease of NAAx demonstrated. Glx levels varied widely in all groups. Levels of NAAx and mIns correlated well with clinical variables. CONCLUSIONS: Metabolite changes suggest neuronal dysfunction and active glial involvement in PLS. The corticomotoneuron is affected in early ALS-B and ALS-L, but at a later stage also in PMA. MR spectroscopy data are useful to obtain insight into the disease process at the level of the upper motor neuron in various phenotypes of MND.
BACKGROUND AND PURPOSE: Upper motor neuron degeneration varies in different phenotypes of MND. We used single-voxel MR spectroscopy of the primary motor cortex to detect corticomotoneuron degeneration and glial hyperactivity in different phenotypes of MND with a relatively short disease duration, contributing to further delineation of the phenotypes. MATERIALS AND METHODS: We prospectively included patients with ALS-B, ALS-L, and PMA and compared their data with those of patients with PLS and healthy controls. Each cohort consisted of 12 individuals. Disease duration was <1 year in ALS and PMA, but longer in PLS by definition. Follow-up examination was at 6 months. We measured ALSFRS-R, finger- and foot-tapping speed, and levels of the following: 1) NAAx, 2) mIns, and 3) Glx in the primary motor cortex. RESULTS: At baseline, we found significantly decreased NAAx levels and increased mIns levels in PLS. Levels of NAAx and mIns in patients with ALS-L and ALS-B were not significantly different from those in controls, but NAAx levels were significantly lower compared with those in PMA. At follow-up, only in PMA was a decrease of NAAx demonstrated. Glx levels varied widely in all groups. Levels of NAAx and mIns correlated well with clinical variables. CONCLUSIONS: Metabolite changes suggest neuronal dysfunction and active glial involvement in PLS. The corticomotoneuron is affected in early ALS-B and ALS-L, but at a later stage also in PMA. MR spectroscopy data are useful to obtain insight into the disease process at the level of the upper motor neuron in various phenotypes of MND.
Authors: H Mitsumoto; A M Ulug; S L Pullman; C L Gooch; S Chan; M-X Tang; X Mao; A P Hays; A G Floyd; V Battista; J Montes; S Hayes; S Dashnaw; P Kaufmann; P H Gordon; J Hirsch; B Levin; L P Rowland; D C Shungu Journal: Neurology Date: 2007-04-24 Impact factor: 9.910
Authors: P Hande Ozdinler; Susanna Benn; Ted H Yamamoto; Mine Güzel; Robert H Brown; Jeffrey D Macklis Journal: J Neurosci Date: 2011-03-16 Impact factor: 6.167
Authors: Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-07 Impact factor: 3.978
Authors: Ian Cheong; Małgorzata Marjańska; Dinesh K Deelchand; Lynn E Eberly; David Walk; Gülin Öz Journal: Neurochem Res Date: 2017-04-03 Impact factor: 3.996
Authors: Daniel Ta; Abdullah Ishaque; Ojas Srivastava; Chris Hanstock; Peter Seres; Dean T Eurich; Collin Luk; Hannah Briemberg; Richard Frayne; Angela L Genge; Simon J Graham; Lawrence Korngut; Lorne Zinman; Sanjay Kalra Journal: Neurology Date: 2021-06-14 Impact factor: 11.800
Authors: Bradley R Foerster; Ruth C Carlos; Ben A Dwamena; Brian C Callaghan; Myria Petrou; Richard A E Edden; Mona A Mohamed; Robert C Welsh; Peter B Barker; Eva L Feldman; Martin G Pomper Journal: Ann Clin Transl Neurol Date: 2014-01-13 Impact factor: 4.511